Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MBIOthis companyMustang Bio, Inc.	$0.39	-2.52×	0.51×	0×	6.62×	606.6%	0.0%	0.0%	0.0%	-20.2%	-25.1%	-109.3%	0×	9.18×	0×	2.22×	0.0%	1	-35.77	2	C+
ACXPAcurx Pharmaceuticals, Inc.	$1.11	-0.47×	0.71×	0×	0.48×	374.0%	0.0%	0.0%	0.0%	-151.2%	-153.6%	-181.9%	0×	0.95×	0×	3.18×	0.0%	2	-10.22	2	B-
BOLTBolt Biotherapeutics, Inc.	$6.22	-0.31×	0.39×	1.33×	-0.67×	-1476.7%	80.6%	-450.1%	-433.7%	-125.9%	-67.7%	-390.3%	0.87×	-0.35×	0×	3.59×	0.0%	2	-18.11	2	C
DWTXDogwood Therapeutics, Inc.	$1.23	-0.96×	0.46×	0×	-0.82×	-43.2%	0.0%	0.0%	0.0%	-45.7%	-32.1%	-45.7%	0×	0.19×	0×	2.76×	0.0%	1	-1.2	3	B
MRKRMarker Therapeutics, Inc.	$1.01	-1.89×	1.36×	0×	-0.54×	20.2%	0.0%	0.0%	0.0%	-72.4%	-76.6%	-52.7%	0×	1.29×	0×	8.39×	0.0%	2	-41.72	2	C
RNAZTransCode Therapeutics, Inc.	$1.59	-0.13×	0.46×	0×	0.38×	1495.1%	0.0%	0.0%	0.0%	-335.4%	-17.6%	-414.4%	0×	0.52×	-4,229.15×	6.29×	0.0%	0	-1.94	3	B
Peer median	—	-0.47×	0.46×	0×	-0.54×	20.2%	0.0%	0.0%	0.0%	-125.9%	-67.7%	-181.9%	0×	0.52×	0×	3.59×	0.0%	2	-10.22	2	—